Use of levodopa decarbozylase inhibitor

No definition available.

Endpoint definition

FinnGen phenotype data
diagram bullet diagram downward connector

Filter registries KELA purch., KELA reimb.

Medicine purchases: ATC N04BA02
Medicine purchases: ATC: other data required >3 instances required

Check pre-conditions None

Include endpoints None

Check conditions None

Apply sex-specific rule None

diagram downward connector PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR

Extra metadata

First used in FinnGen datafreeze DF2

Similar endpoints

List of similar endpoints to Use of levodopa decarbozylase inhibitor based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

None

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals - - -
Unadjusted prevalence (%) - - -
Mean age at first event (years) - - -

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Correlations

Index endpoint: PDMED_LEVODOPA_DECARBOXYLASEINHIBITOR – Use of levodopa decarbozylase inhibitor
GWS hits:

Survival analyses between endpoints

Plot

before Use of levodopa decarbozylase inhibitor
after Use of levodopa decarbozylase inhibitor

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Use of levodopa decarbozylase inhibitor